Reversal of insulin resistance in overweight and obese subjects with tRES-HESP treatment in the HATFF study was associated with decreased dysglycemia, blood pressure, vascular inflammation, and dyslipidemia—a remarkable multiplicity of pathogenic processes. Here, TMPRSS11A is linked to metabolic syndrome.